StockData
Neurocrine Biosciences Inc logo

Neurocrine Biosciences Inc (NBIX) stock

NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/307% below fair value
$165.31−2.09 (-1.25%)

Close on Nov 16, 2026Market cap $16.80BP/E 24.2Yield –

Neurocrine Biosciences cash

Cash and short-term investments held at the end of each period.

Neurocrine Biosciences's cash was $389.80M at Jun 30, 2026. For fiscal 2025 it was $1.48B, up 36.6% from the year before. Over ten years it grew 34.1% a year on average. The highest annual figure on record is $1.48B in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.48B+36.6%
FY2024Dec 31, 2024$1.08B+4.3%
FY2023Dec 31, 2023$1.04B+4.3%
FY2022Dec 31, 2022$997.10M+39.6%
FY2021Dec 31, 2021$714.50M-11.2%
FY2020Dec 31, 2020$804.20M+19.4%
FY2019Dec 31, 2019$673.70M+2.6%
FY2018Dec 31, 2018$656.40M+26.1%
FY2017Dec 31, 2017$520.42M+490.4%
FY2016Dec 31, 2016$88.15M+11.6%
FY2015Dec 31, 2015$78.99M-59.2%
FY2014Dec 31, 2014$193.81M+33.0%
FY2013Dec 31, 2013$145.74M-15.8%
FY2012Dec 31, 2012$173.01M+34.0%
FY2011Dec 31, 2011$129.10M+1.8%
FY2010Dec 31, 2010$126.87M+239.9%
FY2009Dec 31, 2009$37.33M-45.5%
FY2008Dec 31, 2008$68.47M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$389.80M-60.0%
Q1 FY2026Mar 31, 2026$1.32B+39.5%
Q4 FY2025Dec 31, 2025$1.48B+36.6%
Q3 FY2025Sep 30, 2025$1.11B-9.2%
Q2 FY2025Jun 30, 2025$975.60M-6.1%
Q1 FY2025Mar 31, 2025$943.50M-22.1%
Q4 FY2024Dec 31, 2024$1.08B+4.3%
Q3 FY2024Sep 30, 2024$1.23B+12.1%
Q2 FY2024Jun 30, 2024$1.04B+6.4%
Q1 FY2024Mar 31, 2024$1.21B+35.3%
Q4 FY2023Dec 31, 2023$1.04B+4.3%
Q3 FY2023Sep 30, 2023$1.10B+37.0%
Q2 FY2023Jun 30, 2023$976.70M+50.7%
Q1 FY2023Mar 31, 2023$894.60M+34.5%
Q4 FY2022Dec 31, 2022$997.10M+39.6%
Q3 FY2022Sep 30, 2022$799.40M+4.4%
Q2 FY2022Jun 30, 2022$648.30M-26.7%
Q1 FY2022Mar 31, 2022$664.90M-23.9%
Q4 FY2021Dec 31, 2021$714.50M-11.2%
Q3 FY2021Sep 30, 2021$765.90M-18.9%
Q2 FY2021Jun 30, 2021$884.90M-6.7%
Q1 FY2021Mar 31, 2021$873.70M+13.2%
Q4 FY2020Dec 31, 2020$804.20M+19.4%
Q3 FY2020Sep 30, 2020$944.70M+39.9%
Q2 FY2020Jun 30, 2020$948.30M+51.6%
Q1 FY2020Mar 31, 2020$771.70M+45.7%
Q4 FY2019Dec 31, 2019$673.70M+2.6%
Q3 FY2019Sep 30, 2019$675.33M+235.6%
Q2 FY2019Jun 30, 2019$625.49M+263.9%
Q1 FY2019Mar 31, 2019$529.59M+194.5%
Q4 FY2018Dec 31, 2018$656.40M+26.1%
Q3 FY2018Sep 30, 2018$201.21M-26.1%
Q2 FY2018Jun 30, 2018$171.90M-45.3%
Q1 FY2018Mar 31, 2018$179.81M+160.0%
Q4 FY2017Dec 31, 2017$520.42M+490.4%
Q3 FY2017Sep 30, 2017$272.43M+173.1%
Q2 FY2017Jun 30, 2017$314.11M–
Q1 FY2017Mar 31, 2017$69.17M–
Q4 FY2016Dec 31, 2016$88.15M–
Q3 FY2016Sep 30, 2016$99.76M–

More Neurocrine Biosciences figures

See a number that looks wrong?